Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTPEMBRO adjuvant pembrolizumab optimization in early triple-negative breast cancer with pathologic complete response
2024-515787-31-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) and breast cancer comparing Adjuvant pembrolizumab with No adjuvant pembrolizumab / observation (2 arms). Primary endpoint: Recurrence-free survival. Planned start Jul 2025; status: authorised.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2024-515787-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515787-31-00.